Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.41 |
| ▸ | CNR1 | P21554 | 5/20 | 0.40 |
| ▸ | CNR2 | P34972 | 4/20 | 0.40 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5044806 | 0.76 | SLC6A3 (0.37) | SLC6A3SLC6A2CRHR1GABRA2GABRB2 | |
| SCHEMBL14031232 | 0.71 | CNR1 (0.41) | CNR1CNR2 | |
| SCHEMBL2193401 | 0.68 | KMT2A (0.47) | — | |
| SCHEMBL3750813 | 0.67 | CRHR1 (0.75) | CRHR1GABRA2GABRB2ABL1 | |
| SCHEMBL3748688 | 0.66 | CRHR1 (0.61) | CNR1CRHR1GABRA2GABRB2ABL1 | |
| SCHEMBL3521856 | 0.66 | DRD2 (0.41) | SLC6A3SLC6A2CNR1NOTUM | |
| SCHEMBL3522804 | 0.66 | PGR (0.42) | SLC6A3SLC6A2 | |
| SCHEMBL1478595 | 0.66 | ALDH1A1 (0.53) | — | |
| SCHEMBL3520212 | 0.65 | TP53 (0.46) | SLC6A3 | |
| SCHEMBL3758788 | 0.65 | CRHR1 (0.64) | CNR1CNR2CRHR1GABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432283-B2 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432283-B2 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432283-B2 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC (US) | 2008-10-07 | — | — | US | disclosed |
| US-7268146-B2 | Ring fused pyrazole derivatives as CRF antagonists | PALO ALTO LLC (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268146-B2 | Ring fused pyrazole derivatives as CRF antagonists | PALO ALTO LLC (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268146-B2 | Ring fused pyrazole derivatives as CRF antagonists | PALO ALTO LLC (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1718299-A1 | HETEROCYCLIC GABA-A SUBTYPE SELECTIVE RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-08 | — | — | EP | disclosed |
| EP-1453832-B1 | RING FUSED PYRAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-08-09 | — | — | EP | disclosed |
| US-20060135555-A1 | (3,4-Dihydro-1H-isoquinolin-2-yl)-[2-methyl-7-(2,4,6-trimethyl-phenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-b]pyridin-3-yl]-methanone; Corticotropin releasing factor (CRF); stress-related illnesses, mood disorders such as depression, major depressive disorder, single episode depression | ROCHE PALO ALTO LLC | 2006-06-22 | — | — | US | disclosed |
| US-7053103-B2 | Ring fused pyrazole derivatives as CRF antagonists | SYNTEX (U.S.A.) LLC (US) | 2006-05-30 | — | — | US | disclosed |
| US-20050197330-A1 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC | 2005-09-08 | — | — | US | disclosed |
| WO-2005077363-A1 | HETEROCYCLIC GABA-A SUBTYPE SELECTIVE RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-25 | — | — | WO | disclosed |
| US-20050014781-A1 | Ring fused pyrazole derivatives as CRF antagonists | LOUGHHEAD DAVID GARRETT (US) | 2005-01-20 | — | — | US | disclosed |
| US-6821984-B2 | FOR THERAPY OF PSYCHIATRIC DISORDERS AND NEUROLOGICAL DISEASES | SYNTEX (U.S.A.) LLC | 2004-11-23 | — | — | US | disclosed |
| EP-1453832-A1 | RING FUSED PYRAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2004-09-08 | — | — | EP | disclosed |
| US-20040006066-A1 | Ring fused pyrazole derivatives as CRF antagonists | SYNTEX (U.S.A.) LLC | 2004-01-08 | — | — | US | disclosed |
| WO-2003048160-A1 | RING FUSED PYRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135555-A1 | (3,4-Dihydro-1H-isoquinolin-2-yl)-[2-methyl-7-(2,4,6-trimethyl-phenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-b]pyridin-3-yl]-methanone; Corticotropin releasing factor (CRF); stress-related illnesses, mood disorders such as depression, major depressive disorder, single episode depression | CRHR1, CRH, CRHR2 | SLC6A3 727/4885SLC6A2 615/4885CNR1 34/4885 |
| US-20050197330-A1 | Heterocyclic GABAA subtype selective receptor modulators | GABRA2, GABRA1, GABRA5 | SLC6A3 588/4885SLC6A2 396/4885CNR1 23/4885 |
| US-20050014781-A1 | Ring fused pyrazole derivatives as CRF antagonists | CRHR1, CRHR2, MC2R | SLC6A3 551/4885SLC6A2 664/4885CNR1 6/4885 |
| US-20040006066-A1 | Ring fused pyrazole derivatives as CRF antagonists | CRHR1, CRHR2, MC2R | SLC6A3 560/4885SLC6A2 623/4885CNR1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.